Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3437943 in obesity under calorie restriction
NCT06313528Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2024
- Primary completion
- Aug 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing LY3437943 with Placebo (2 arms). Primary endpoint: Change from Baseline in Total Calorie Intake at Lunch and Dinner (Combined) at 17 weeks. Started Mar 2024; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06313528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06313528.